What is the evidence-based impact of tranexamic acid on trauma mortality when used early?

What is the evidence-based impact of tranexamic acid on trauma mortality when used early?

• A. Reduces mortality due to hemorrhage when given early (within 3 hours; ideally within 1 hour)
• B. Increases mortality
• C. No effect
• D. Only reduces morbidity

Answer: (D)

Early tranexamic acid in trauma reduces death from bleeding when given promptly, with the greatest benefit seen when administered within the first hour and within a three-hour window overall. The antifibrinolytic action blocks plasmin formation, helping to stabilize clots and limit ongoing hemorrhage. Large trials show a real reduction in death due to bleeding after injury, and overall mortality can also be reduced without a meaningful rise in thromboembolic complications. So the strongest evidence supports a mortality benefit from hemorrhage when TXA is given early, not merely a reduction in morbidity.

Early tranexamic acid in trauma reduces death from bleeding when given promptly, with the greatest benefit seen when administered within the first hour and within a three-hour window overall. The antifibrinolytic action blocks plasmin formation, helping to stabilize clots and limit ongoing hemorrhage. Large trials show a real reduction in death due to bleeding after injury, and overall mortality can also be reduced without a meaningful rise in thromboembolic complications. So the strongest evidence supports a mortality benefit from hemorrhage when TXA is given early, not merely a reduction in morbidity.